Rapid Therapeutic Science Laboratories, Inc.
Rapid Therapeutic Science Laboratories, Inc.
Your view on RTSL
Overview
What the company does, where it operates, and who runs it.
About Rapid Therapeutic Science Laboratories, Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Donal R. Schmidt Jr.
- Headquarters
- 5580 Peterson Lane, Dallas, TX, US
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Donal R. Schmidt Jr.
- Headquarters
- 5580 Peterson Lane, Dallas, TX, US
Rapid Therapeutic Science Laboratories, Inc. operates as a biotech company. The company engages in the aerosol delivery of non-psychoactive cannabinoids to the blood stream for treatment of chronic pain, post-traumatic stress disorder, insomnia, surgery recovery, and other ailments.
It offers pressurized meter dose inhaler, a device that delivers a measured amount of aerosolized inhalant in a mist to the lungs; sublingual oral spray devices; and water-soluble cannabidiol and cannabigerol isolates under the nhaler brand.
The company was formerly known as Holly Brothers Pictures, Inc. and changed its name to Rapid Therapeutic Science Laboratories, Inc. in January 2020. Rapid Therapeutic Science Laboratories, Inc. was incorporated in 2013 and is based in Dallas, Texas. Rapid Therapeutic Science Laboratories, Inc. was a former subsidiary of Texas Mdi, Inc.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Rapid Therapeutic Science Laboratories, Inc., and the rating behind it. RTSL last traded at $0.0060; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Rapid Therapeutic Science Laboratories, Inc.. Starting points for Rapid Therapeutic Science Laboratories, Inc.: EPS -$0.0095, beta -1.76 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Rapid Therapeutic Science Laboratories, Inc.. Rapid Therapeutic Science Laboratories, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Rapid Therapeutic Science Laboratories, Inc.. Trailing twelve-month EPS for Rapid Therapeutic Science Laboratories, Inc. stands at -$0.0095. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Rapid Therapeutic Science Laboratories, Inc.. Rapid Therapeutic Science Laboratories, Inc. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Rapid Therapeutic Science Laboratories, Inc. valued side by side against its closest peers. Rapid Therapeutic Science Laboratories, Inc. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Rapid Therapeutic Science Laboratories, Inc., and how their positions are changing. At a $52,994 market value, institutional positions materially move Rapid Therapeutic Science Laboratories, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Rapid Therapeutic Science Laboratories, Inc. executives and directors. Shares of Rapid Therapeutic Science Laboratories, Inc. have traded between $0.0010 and $0.0080 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Rapid Therapeutic Science Laboratories, Inc.. Rapid Therapeutic Science Laboratories, Inc. is a $52,994 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Rapid Therapeutic Science Laboratories, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Rapid Therapeutic Science Laboratories, Inc.. Coverage tracks Rapid Therapeutic Science Laboratories, Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.